

The Symplicity™ Blood Pressure Procedure

# Renal denervation

An adjunctive treatment for uncontrolled hypertension.

## The need

Hypertension is highly prevalent with **<20% of patients achieving blood pressure control** despite existing treatment options.<sup>1</sup>





# 20%

reduction in relative risk of **major cardiovascular events** (MACE) with each 10 mmHg decrease in mean OSBP.<sup>2</sup>

## The Symplicity procedure

The Symplicity Spyral™ Renal Denervation System is a minimally-invasive interventional approach to safely achieve BP reductions.<sup>3-7</sup>

- **Helical pattern** to ablate all 4 quadrants simultaneously<sup>8</sup>
- **One catheter** size fits all eligible anatomy (vessels 3-8 mm)<sup>8,9</sup>
- **Automatically** monitors and safely controls power to each electrode, independently<sup>9</sup>



## Radiofrequency (RF) energy

Radiofrequency (RF) energy is delivered to disrupt the overactive sympathetic signalling between kidneys and the brain to reduce blood pressure.<sup>9</sup> Kidneys modulate sympathetic tone via the renal nerves to control blood pressure.

# The evidence

The Symplicity™ Blood Pressure Procedure is **proven** to provide **safe** and **effective** blood pressure reductions that are **"always on"**.<sup>3-6</sup>

## ✔ Significant

>9 mmHg reduction in OSBP at 3 - 6 months.<sup>3-6,10</sup>

- Consistent BP reductions across trials, in both the presence and absence of medications<sup>3-6</sup>

## ✔ Safe

Excellent safety profile.<sup>3-7</sup>

- No new incidence of renal artery stenosis at 6 months<sup>6</sup>
- Minimal decline in eGFR through 3 years in Medtronic GSR<sup>7</sup>

## ✔ Sustained

>18 mmHg reduction in OSBP at 3 years.<sup>10,11</sup>

- Sustained reductions at 3 years in >1500 patients<sup>11-13</sup> and out to ~10 years in independent research<sup>14,15</sup>

# The right patient

ESC/EAPCI clinical consensus statement recommends renal denervation as an **adjunctive treatment** to lifestyle and pharmacological intervention and identifies patients who can benefit.<sup>16</sup>



### Uncontrolled resistant hypertension patients with

- Office BP  $\geq 140/\geq 90$  mmHg confirmed by ABPM
- Treated with  $\geq 3$  meds
- eGFR  $\geq 40$  ml/min/1.73 m<sup>2</sup>



### Patients intolerant to medications

- Patient preference integrated in a shared decision-making process



### Patients at high global cardiovascular risk

#### References

1. Mills KT, et al. *Nat Rev Nephrol.* 2020; 16(4):223-237.
2. Ettehad D, et al. *The Lancet.* 2016;387:957-967.
3. Townsend RR, et al. *The Lancet.* 2017;390(10108):2160-2170.
4. Böhm M, et al. *The Lancet.* 2020;395(10234):1444-1451.
5. Kandzari DE, et al. *The Lancet.* 2018;391(10137):2346-2355.
6. Kandzari et al, AHA 2022
7. Goncalves P. PCR e-Course 2020
8. Medtronic Symplicity Spyral™ Instructions for Use
9. Coates P, et al. *Cardiovascular Revascularization Medicine.* 42 (2022) 171-177
10. Schlaich Kidney Week 2021
11. Mahfoud F, et al. *The Lancet.* 2022; 399: 1401-10.
12. Mahfoud EuroPCR 2022
13. Bhatt DL, et al. *The Lancet.* 2022;400(10361):1405-1416.
14. Sesa-Ashton G, et al. *Hypertension.* 2023;80.
15. Al Ghorani et al. *JACC* Vol. 81, No. 5 2023
16. Barbato E, et al. *Eur Heart J.* Published online Feb 15 2023

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at [www.medtronic.eu](http://www.medtronic.eu).

For applicable products, consult instructions for use on [manuals.medtronic.com](http://manuals.medtronic.com). Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan or France.

#### Europe

Medtronic International Trading Sàrl.  
Route du Molliau 31  
Case postale  
CH-1131 Tolochenaz  
[www.medtronic.eu](http://www.medtronic.eu)  
Tel: +41 (0)21 802 70 00  
Fax: +41 (0)21 802 79 00

UC202311747-renal-denervation-one-pager-en-we-8625728  
© 2023 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.



Scan to  
deep dive